Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Abstract

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.

References 487

1. 1.

   Paget, S. A., Lockshin, M. D. & Loebl, S. The hospital for special surgery rheumatoid arthritis handbook: everything you need to know. (Wiley, 2002).

   Not in our library

2. 2.

   Senthelal, S., Li, J., Ardeshirzadeh, S. & Thomas, M. A. in StatPearls (StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC., 2022).

   Not in our library

3. 3.

   Landré-Beauvais AJ. The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Jt. Bone Spine. 2001;68:130-143.

   Not in our library10.1016/s1297-319x(00)00247-5

4. 4.

   Garrod, A.B. The nature and treatment of gout and rheumatic gout. Br. Foreign Med. Chir. Rev. 25, 419–435 (1860).

   Not in our library

5. 5.

   Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038.

   Not in our library10.1016/s0140-6736(16)30173-8

6. 6.
   Management of Rheumatoid Arthritis: An Overview · 2021

   No notice
7. 7.

   Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 2019;33:101477.

   Not in our library10.1016/j.berh.2019.101477

8. 8.

   Wasserman A. Rheumatoid arthritis: common questions about diagnosis and management. Am. Fam. Physician. 2018;97:455-462.

   Not in our library

9. 9.

   Almutairi K, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol. Int. 2021;41:863-877.

   Not in our library10.1007/s00296-020-04731-0

10. 10.

    Safiri S, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann. Rheum. Dis. 2019;78:1463-1471.

    Not in our library10.1136/annrheumdis-2019-215920

11. 11.

    Azer SA, AlSwaidan NM, Alshwairikh LA, AlShammari JM. Accuracy and readability of cardiovascular entries on Wikipedia: are they reliable learning resources for medical students? BMJ Open. 2015;5:e008187.

    Not in our library10.1136/bmjopen-2015-008187

12. 12.

    Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182-188.

    Not in our library10.1016/j.semarthrit.2006.08.006

13. 13.

    Goodson N, Symmons D. Rheumatoid arthritis in women: still associated with an increased mortality. Ann. Rheum. Dis. 2002;61:955-956.

    Not in our library10.1136/ard.61.11.955

14. 14.

    Kolarz K, Targońska-Stępniak B, Majdan M. [Early reumatoid arthritis]. Wiad. Lek. 2018;71:1061-1065.

    Not in our library

15. 15.

    Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51:vi5-vi9.

    Not in our library10.1093/rheumatology/kes279

16. 16.

    Bykerk VP, Massarotti EM. The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic? Rheumatology. 2012;51:vi10-vi15.

    Not in our library10.1093/rheumatology/kes280

17. 17.

    Mjaavatten MD, Bykerk VP. Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA. Best. Pract. Res. Clin. Rheumatol. 2013;27:451-466.

    Not in our library10.1016/j.berh.2013.09.001

18. 18.

    Coutant F, Miossec P. Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Curr. Opin. Rheumatol. 2020;32:57-63.

    Not in our library10.1097/bor.0000000000000664

19. 19.

    Kurko J, et al. Genetics of rheumatoid arthritis - a comprehensive review. Clin. Rev. Allergy Immunol. 2013;45:170-179.

    Not in our library10.1007/s12016-012-8346-7

20. 20.

    Sparks JA. Rheumatoid arthritis. Ann. Intern Med. 2019;170:Itc1-itc16.

    Not in our library10.7326/aitc201901010

21. 21.

    Figus FA, et al. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun. Rev. 2021;20:102776.

    Not in our library10.1016/j.autrev.2021.102776

22. 22.

    Pope JE. Management of fatigue in rheumatoid arthritis. RMD Open. 2020;6:e001084.

    Not in our library10.1136/rmdopen-2019-001084

23. 23.

    Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am. J. Med. 2007;120:936-939.

    Not in our library10.1016/j.amjmed.2007.04.005

24. 24.

    Cush JJ. Rheumatoid arthritis: early diagnosis and treatment. Med. Clin. North Am. 2021;105:355-365.

    Not in our library10.1016/j.mcna.2020.10.006

25. 25.

    Zhao J, Li ZG. The challenges of early diagnosis and therapeutic prediction in rheumatoid arthritis. Int J. Rheum. Dis. 2018;21:2059-2062.

    Not in our library10.1111/1756-185x.13459

26. 26.

    Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Prim. Care. 2018;45:237-255.

    Not in our library10.1016/j.pop.2018.02.010

27. 27.

    Li X, Su Y. [Diagnosis and treatment of early rheumatoid arthritis]. Zhonghua Nei Ke Za Zhi. 2020;59:724-727.

    Not in our library10.3760/cma.j.cn112138-20200703-00644

28. 28.

    Cush JJ. Rheumatoid arthritis: early diagnosis and treatment. Rheum. Dis. Clin. North Am. 2022;48:537-547.

    Not in our library10.1016/j.rdc.2022.02.010

29. 29.

    da Mota LM, et al. Imaging diagnosis of early rheumatoid arthritis. Rev. Bras. Reumatol. 2012;52:757-766.

    Not in our library

30. 30.

    Galvez-Sánchez CM, et al. Attentional function in fibromyalgia and rheumatoid arthritis. PLoS One. 2021;16:e0246128.

    Not in our library10.1371/journal.pone.0246128

31. 31.

    Thomas DC, et al. Orofacial manifestations of rheumatoid arthritis and systemic lupus erythematosus: a narrative review. Quintessence Int. 2021;52:454-466.

    Not in our library10.3290/j.qi.b1043985

32. 32.

    Rose J. Autoimmune connective tissue diseases: systemic lupus erythematosus and rheumatoid arthritis. Emerg. Med. Clin. North Am. 2022;40:179-191.

    Not in our library10.1016/j.emc.2021.09.003

33. 33.

    Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin. Arthritis Rheum. 2016;46:291-304.

    Not in our library10.1016/j.semarthrit.2016.05.012

34. 34.

    Cross M, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 2014;73:1316-1322.

    Not in our library10.1136/annrheumdis-2013-204627

35. 35.

    Roodenrijs NMT, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology. 2021;60:3778-3788.

    Not in our library10.1093/rheumatology/keaa860

36. 36.

    Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22:1-12.

    Not in our library10.2165/00019053-200422001-00002

37. 37.

    Furneri G, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin. Exp. Rheumatol. 2012;30:S72-S84.

    Not in our library

38. 38.

    Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur. J. Health Econ. 2008;8:95-106.

    Not in our library10.1007/s10198-007-0091-0

39. 39.

    Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 2011;70:8-14.

    Not in our library10.1136/ard.2010.142133

40. 40.

    Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull. World Health Organ. 2003;81:646-656.

    Not in our library

Cited by papers we hold 3

• Neutrophil extracellular traps in homeostasis and disease · 2024
  No notice
• Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders · 2024
  Corrected
• Targeting strategies for bone diseases: signaling pathways and clinical studies · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.